Associated Genetic Biomarkers
EGFR R831H is present in 0.11% of AACR GENIE cases, with acute myeloid leukemia, histiocytic and dendritic cell neoplasm, and pancreatic adenocarcinoma having the greatest prevalence .
EGFR R831H serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains EGFR R831H as an inclusion criterion, 1 is phase 2 (1 open).
Trials with EGFR R831H in the inclusion eligibility criteria most commonly target breast carcinoma, diffuse midline glioma, H3 K27M-mutant, gastric carcinoma, glioblastoma, and malignant solid tumor .
Poziotinib is the most frequent therapy in trials with EGFR R831H as an inclusion criteria .
Significance of EGFR R831H in Diseases
Breast Carcinoma +
Colorectal Carcinoma +
Diffuse Midline Glioma, H3 K27M-Mutant +
EGFR is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients .
EGFR R831H is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains EGFR R831H and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) .
Gastric Carcinoma +
Malignant Solid Tumor +
EGFR is altered in 7.61% of malignant solid tumor patients with EGFR R831H present in 0.0% of all malignant solid tumor patients .
EGFR R831H is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains EGFR R831H and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
WHO Grade III Glioma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.